Metastases and the normalization of tumour blood vessels by ICRF 159: a new type of drug action
about
Stromal Claudin14-heterozygosity, but not deletion, increases tumour blood leakage without affecting tumour growthInduction of thrombospondin-1 partially mediates the anti-angiogenic activity of dexrazoxaneCombination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamicsExploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunitiesUtility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicityEffect of stereoisomers related to ICRF-159 on metastasis of B16 melanomaImproved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiationEffect of pazopanib on tumor microenvironment and liposome deliveryLysosomes in cancer cells.Influence of soluble or matrix-bound isoforms of vascular endothelial growth factor-A on tumor response to vascular-targeted strategies.The radiation response of sarcomas by histologic subtypes: a review with special emphasis given to results achieved with razoxaneInfluence of ICRF 159 and trition WR 1339 on metastases of a rat epithelioma.ICRF-159 enhancement of radiation response in combined modality therapies. I. Time/dose relationships for tumour response.Histamine receptor antagonism and anti-tumour activity.Anti-angiogenic therapies in cancer clinical trials.Tumour angiogenesisImproving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming.Neural progenitor cell-mediated delivery of interferon beta improves neuroblastoma response to cyclophosphamide.Remodeling of tumor stroma and response to therapy.Tumor vasculature as target for therapeutic intervention.Current status of antiangiogenic therapies for glioblastomas.Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies.Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane.Complex effects of tumor microenvironment on the tumor disposition of carrier-mediated agents.Changes in sensitivity to radiation and ICRF 159 during the life of monolayer cultures of EMT6 tumour line.Tumor vessel disintegration by maximum tolerable PFKFB3 blockade.Rediscovery in science-a second eureka moment? A case in the neovascularization in cancer.Combination therapy of radiofrequency ablation and bevacizumab monitored with power Doppler ultrasound in a murine model of hepatocellular carcinoma
P2860
Q21133542-69D05298-EF4E-4948-B4AC-0499A1BE4AAEQ24314623-7BFFFC37-BAAA-4F11-9735-9B326F2B58DFQ26746067-DE227443-0DBD-49FA-82B0-92FBFD6D5979Q26828930-35039C47-1E03-477B-95B8-030C2D3822D8Q28301317-1ACC358B-99AE-4D2C-A83D-90E92E5978D7Q28366945-435FFBF9-991F-4567-B609-ACC92E28F5C6Q33756489-5D93D4F8-6900-44A3-8535-B612EF62118EQ34018204-81FD447F-409F-43C8-87D0-589806B8C0E6Q34303056-9EE388BF-8B5A-490B-81C6-C592ADDA2E92Q34742649-7AA2CE7E-A854-4C0A-9B34-46687F3C9E39Q34795318-77D078AD-E30A-4E09-A539-3378085C1C3EQ36041461-60D03F64-BB5F-4F01-914B-267E90DFC71EQ36043008-993215EB-0C63-4289-8288-BD325C01D4D2Q36047083-4B625AE9-850A-4B0A-9EB9-668F45176B6CQ36181120-48C566F2-48B3-4993-A8F2-323E21D2E71DQ36817023-6366CF75-78F8-4370-81B9-803F890423A1Q36848111-8DE6B241-3113-4C32-9DA0-E786CBEF678DQ36983025-F76A11B7-CED2-4A1F-B3CA-6CB74AF6C0F3Q37016995-49505F67-A777-4F0A-A0CE-23FBF8ADD609Q37800110-541E19A5-E724-4EE0-BDBF-795D9403C25CQ38169761-BB8A1182-1E93-43F4-B6CE-6442A61EF890Q38255001-A6187DF6-2909-42AA-8840-4800BA18BCF0Q38601825-94A37443-88D8-4718-B61E-9C7DB6B64A21Q39458957-45F6CBBF-D35F-4B57-B59F-E337C13B0364Q42578778-79F51284-AFCD-4626-A795-24F61C06A367Q50217994-9EF14B22-0572-46DB-BA6C-26B6E1FC07B3Q52668294-ADC23C40-B728-4D01-8FC2-D966F31C4523Q57317511-F37CE05B-A516-43FE-B640-DD75B12E02D6
P2860
Metastases and the normalization of tumour blood vessels by ICRF 159: a new type of drug action
description
1972 nî lūn-bûn
@nan
1972 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1972 թվականի մարտին հրատարակված գիտական հոդված
@hy
1972年の論文
@ja
1972年論文
@yue
1972年論文
@zh-hant
1972年論文
@zh-hk
1972年論文
@zh-mo
1972年論文
@zh-tw
1972年论文
@wuu
name
Metastases and the normalizati ...... 159: a new type of drug action
@ast
Metastases and the normalizati ...... 159: a new type of drug action
@en
Metastases and the normalizati ...... 159: a new type of drug action
@nl
type
label
Metastases and the normalizati ...... 159: a new type of drug action
@ast
Metastases and the normalizati ...... 159: a new type of drug action
@en
Metastases and the normalizati ...... 159: a new type of drug action
@nl
prefLabel
Metastases and the normalizati ...... 159: a new type of drug action
@ast
Metastases and the normalizati ...... 159: a new type of drug action
@en
Metastases and the normalizati ...... 159: a new type of drug action
@nl
P2860
P3181
P356
P1433
P1476
Metastases and the normalizati ...... 159: a new type of drug action
@en
P2093
A W Le Serve
K Hellmann
P2860
P304
P3181
P356
10.1136/BMJ.1.5800.597
P407
P577
1972-03-04T00:00:00Z